purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation nv earnings call period ending march image source motley fool novartis ag nv q earnings callapr etcontents prepared remark question answer call participant prepared remark operatorgood morning good afternoon welcome novartis q result release conference call live webcast operator instruction conference recorded operator instruction recording conference call including qa session available website shortly call end would like hand m sloan simpson head investor relation please go ahead madamsloan simpson head investor relation thank much operator good morning good afternoon everyone thank joining firstquarter earnings call information presented today contains forwardlooking statement involve known unknown risk uncertainty factor may cause actual result materially different future result performance achievement expressed implied statement description factor please refer company form f recent quarterly result form k respectively filed furnished yous security exchange commission hand across vasvas narasimhan chief executive officer thank sloan would like open today call first thanking samir shah incredible tenure head investor relation decade grateful contribution look forward continued contribution new role novartis want welcome sloan simpson think sloan absolutely outstanding job serving head investor relation worked many many year think really pleased grateful board let u turn quarter novartis delivered really strong start year doubledigit sale growth core margin expansion enabled u upgrade guidance harry go guidance detail sale constant currency core operating income core margin reached steadily march goal plus addition number important innovation milestone quarter go course call would want particularly highlight fabhalta positive opinion enables u launch fabhalta europe scemblix firstline readout think important major medicine company also updated psma o result enable u move forward filing pluvicto united state moving slide growth quarter broad based strong contribution many key growth driver including entresto kesimpta cosentyx strong quarter well kisqali would also say geographically performance broadbased strong growth across yous europe china strong growth japan see chart strong growth indicated constant currency growth expect growth continue course year give u confidence upgraded guidance outlined morning moving slide walk brand one one always first entresto doubledigit growth quarter geographically broadbased yous ex yous yous weekly trx continue reach new high constant currency growth outside yous continue see momentum brand strong guideline position yous europe penetration opportunity heart failure globally specifically hypertension china japan japan protection early medicine forecasting purpose change entresto loe outlook continue guide mid loe continuing aggressively defend various patent term eu continue guide rdp november benefiting pediatric extension moving slide cosentyx grew quarter think really got back dynamic growth expect medicine fueled core indication also strong launch go bit detail yous constant currency ex yous highly highly competitive core indication saw return market share improvement psoriasis rheumatology indication yous europe leading originator biologic il class eu china term new launch saw strong performance h hidradenitis superatevia nbrx share versus adalimumab yous germany compare launch comparable basis adalimumab launch indication currently see nearly three time performance previous launch think really highlighting strong uptake cosentyx new indication also strong performance intravenous indication ahead j code expect july think indicates strong interest iv option patient cosentyx rheumatology indication look forward acceleration back half year j code place moving slide kesimpta delivered growth quarter global yous ex yous driven patient treated worldwide medicine majority patient either naive first switch reflects strategy brand yous saw strong demanddriven growth nbrx volume plus versus prior quarter one key priority yous increase bcell market share coming quarter outside yous leadership seven major market look forward continuing drive convenience high efficacy story kesimpta present market quarter well announced alethia sixyear longterm data demonstrated sustained efficacy consistent safety profile kesimpta study nine patient free net three score disease activity also saw treatmentnaive patient derive substantial benefit across multiple marker disease activity even face competitor launch feel confident one minute month selfadministered dosing high efficacy strong safety profile kesimpta moving slide kisqali grew metastatic breast cancer continued leading share new patient start yous think increasing recognition unique profile kisqali offer given broad data set o across three different study metastatic breast cancer leading nbrx share see steady growth writer also working increase depth well improve market access position across key account ahead early breast cancer launch outside united state growth fastestgrowing cdk europe market leader premenopausal indication also successfully entered nrdl list china quarter early day china given strength china operation hopeful draw dynamic growth kisqali china time regulatory review early breast cancer ongoing filed yous eu currently expect regulatory review proceed planned manufacturing adjustment disclosed week ago track assure alignment latest regulatory standard early breast cancer end q continue expect able launch medicine second half year moving slide pluvicto strong growth quarter driven new patient start early beginning growth well outside yous treatment site running yous steady progress goal get well site fully certified use pluvicto also supply performance consistently high level injection administered planned day ample supply indianapolis facility running continued expansion manufacturing network really feel like position fully supply market consistently globally medicine course going focus share expansion within existing site particularly expanding referral network medical oncologist refer pluvictotreating center feel like key posttaxane setting also want build business outside united state important launch europe also build toward launch planned launch japan china country planned new manufacturing facility support pluvicto lutathera business existing indication also track announced earlier quarter psmafore submissionenabling o readout achieved put u position file pluvicto early second half midyear filing medicine psma addition also track well psma delayed castration localized algo metastatic program well little detail psmafore submissionenabling o readout primary endpoint read last year met primary endpoint well really strong data across secondary exploratory endpoint impressive relative risk reduction rpfs strong profile across patientreported outcome well various response orr dcr dor announced earlier quarter updated third interim gave u higher proportion o event o hazard ratio le one put u position file midyear secondary endpoint consistent previous result rpfs feel see additional eight month followup high confidence safety profile pluvicto result presented upcoming medical congress course working quickly get file moving slide like also really strong quarter adoption expanded steadily yous also outside united state see lefthand chart strong performance yous outside yous taking yous first growth outpacing advanced lipid lowering market nearly facility ordering increased breadth depth across key account continue see buy bill key driver overall business see also use channel well outside yous consistent rollout country publicly reimbursed additional private commercial coverage put u strong position top european market contributing international sale really strong growth across international region strong early uptake china selfpay setting new patient day ahead planned nrdl listing first half first part next year lastly new data acc publication well supported early initiation demonstrating starting early patient requiring secondary prevention cardiovascular event lot patient achieve ldlc goal earlier moving next slide slide scemblix grew quarter primarily driven third line indication firstline submission track completed coming month continued momentum core third line indication nbrx share outside yous total market share driven key market japan france germany third line setting primarily focus early identification patient could benefit switch scemblix post two tkis reminder ascfirst study enabled firstinline submission firstline submission half one primary endpoint met versus standard care tkis versus gleevec well favorable safety tolerability profile confirm full data presented asco turning fabhalta early stage pnh launch expect really see significant sale early stage given complexity launch pleased early launch indicator rapid increase number hcps certified rem program increase new rider patient start exceeding internal expectation see uptake across naive switch patient medicine also really happy see hcps willing work medical exception process get patient medicine also positive chmp opinion pnh expect full approval happen coming month consistently work launch medicine across globe well drive rapid uptake united state turning slide also announced phase applause igan study full result earlier quarter demonstrated proteinuria reduction relative placebo study randomized patient eptacopan versus placebo result read ninemonth interim proteinuria analysis patient continue followed month full egfr analysis see righthand panel impressive proteinuria reduction versus placebo clinically meaningful statistically significant know complement activation key driver inflammation igan importantly overall safety profile consistent data previously reported submitted data fda one clarification use priority review voucher medicine fda granted u priority review based data set provided study continues well egfr readout look forward really getting full approval shortly getting initial approval coming period moving slide remibrutinib demonstrated already demonstrated earlier study week robust efficacy safety needed wait week data position file chronic spontaneous urticaria data came positive enabling u move forward toward important filing reminder csu patient yous controlled refractory antihistamine le patient currently biologics large opportunity highefficacy oral medicine previous primary endpoint data week shown consistently showed improvement versus placebo week uas score look forward presenting full data set second quarter medicine week consistent favorable safety profile demonstrated overall rate comparable placebo balanced liver function test well clear efficacy data look forward global submission second half remibrutinib taken together track across innovation goal year want highlight shifted ataclopan cg yous submission second half great correlate efficacy cg given ultrarare nature disease provided fda sixmonth data certainly believe sixmonth data compelling fda wanted see additional month followup patient patient rolled onto active first month period randomized second month period patient inactive complete month followup file second half remain excited opportunity bring well patient cg moving next slide also track range submission continue keep abreast data set unfold well potential readout time line understand readout time line better really excited catalystrich profile coming year moving slide hand harryharry kirsch chief financial officer yeah thank much va good morning good afternoon everyone going walk financials first quarter always comment refer growth rate constant currency unless otherwise noted also throughout presentation refer continuing operation see number strong start year slide see summary financial performance net sale core operating income core margin grew basis point reach showing well track achieve midterm margin guidance plus core eps first quarter growing bit ahead corbin due share buyback program free cash flow billion declining versus quarter due prior year onetimer timing tax payment year however importantly full year free cash flow expected grow approximately line core operating income summary strong start year effort focus streamline business continue pay brings u already full year guidance slide strong momentum business across inmarket growth brand launch yous international market give u confidence upgrade top bottom line guidance also favorable update generic entry assumption yous actually smaller element analysis driving guidance upgrade expect net sale grow range high single digit low double digit core operating income grow range low double digit midteens underpinning guidance two key assumption entresto promacta generic launch yous complete full year guidance please note continue expect core net financial expense range billion billion core tax rate around moving slide pleased quality quarter sale growth driven key inmarket brand grew va showed also prior slide quarter vast majority brand still many year patent protection ahead continued momentum strongly support midterm growth outlook cagr slide please highlight continue shareholderfriendly capital allocation strategy quarter course investing business alongside returning capital shareholder notably q announced two valuecreating boltons core therapeutic area proposed acquisition morphosys licensing deal align strategic focus oncology term returning capital shareholder paid billion growing dividend quarter also continue billion share buyback program still billion remaining executed end already final slide outlined detail regarding fx impact see quarter fx negative impact sale point negative core operating income latter driven strong swiss franc late april rate prevail including recent strengthening yous dollar expect fullyear impact currency still le top line negative bottom line negative reminder hard forecast outside moving time updating expected fx impact website monthly basis hand back vasvas narasimhan chief executive officer great thanks harry heard strong start year doubledigit sale growth strong core margin expansion strong momentum see business able raise guidance year saw momentum across key growth brand across geography think indicating high quality performance seeing company pipeline continues advance multiple submission submissionenabling readout outlined continue confidence midterm guidance constant currency sale growth plus core operating income margin hand back sloan outline upcoming investor eventssloan simpson head investor relation thank va open question wanted flag investor event planning hold year first inperson event asco chicago june nd highlighting alcon asco data va mentioned also virtual event renal pipeline second half year annual meet novartis management event london november hope see many event operator let u open line question please question answer operatorthank operator instruction first question come line matthew weston ubs please go aheadmatt weston ubs analyst thank taking question going pluvicto va set metric term improving revenue think definitely expectation among investor might see inflection supply come online physician get comfortable ability supply add nurse chair network wanted understand whether thought realistic assumption whether investor get comfortable kind continuous grind growth pluvicto coming quartersvas narasimhan chief executive officer yeah thanks matthew first pluvicto resolved supply issue still working think remnant base patient bit lower quarter given still working thing think growth pluvicto medium long term first posttaxane indication see already annualizing pretty healthy blockbuster billion plus sale range expect steadily grow guided indication multibillion dollar billionplus indication expect steadily grow coming quarter posttaxane setting primarily driven mentioned expanding base medical oncologist able refer existing center see opportunity point term expanding number center indication steadily grow course get u steadily marching toward multibillion dollar guidance billionplus guidance given vision indication expect psmafore pretaxane indication next catalyst expect inflection launch also mention pluvicto outside yous well get additional momentum bring board germany france country europe coming year expect substantial inflection china japan building dedicated manufacturing facility country order drive growth pretaxane post taxing indication next catalyst pretaxane approval hope first half next year hormonesensitive indication algo metastatic also two program advancing actinium psma well also bolster overall portfolio think steady growth vision indication within catalyst coming ex yous expansion indication expansion brand thanks matthew next question operatoroperatorthank next question come line steve scala td cowen please go aheadsteve scala td cowen analyst thank much noted prepared remark kisqali review track confident novartis fda meet priority review regulatory deadline kisqali broad label seems number thing could give fda pause including nitrosamine issue well liver tox level confidence thank youvas narasimhan chief executive officer yes steve confident broad label think time line currently guide current time line implement manufacturing shift course discussing manufacturing adjustment minor adjustment require discussion fda better clarity shift time line would course let market know think still secondhalf launch medicine feel good guidance talk minor shift talking anything significant expect broad label concern liver something well known kisqali currently monitored metastatic breast cancer setting change monitoring requirement expect overall feel good ability launch medicine second half year thank next question operatoroperatorthank next question come line graham parry bank america please go aheadgraham parry bank america merrill lynch analyst ok thanks taking question another one kisqali could explain process amendment needed kisqali early breast cancer something actual reaction purification know moment whether need inspection fda one think would still completed within second quarter time frame therefore delay naturally produce time line thank youvas narasimhan chief executive officer graham first manufacturer adjustment talk reminder kisqali already meet requirement metastatic breast cancer additional requirement given early breast cancer asymptomatic population adjustment talked primarily source material third party want go higher quality sourcing thirdparty material something believe implement straightforward way also additional adjustment within supply chain management kisqali prior actually leaving supply chain go physician believe relatively minor change nonetheless change need review regulator term inspection believe would inspection required think overall give u confidence guidance launch medicine second half thank next question operatoroperatorthank next question come line emily field barclays please go aheademily field barclays analyst hi thanks taking question want ask question cosentyx know mentioned second j code currently generating much sale iv formulation context could frame current pricing environment yous specifically thank youvas narasimhan chief executive officer yeah thanks emily cosentyx iv would say betterthanexpected uptick thought prior j code look cosentyx current outperformance quarter driven primarily strong hidradenitis suprativo launch well leading stronger performance well psoriasis globally iv launch still think midst kicking would say reached already vast majority account expected order cosentyx iv already least process ordering medicine ahead j code trying use exceptional code use medicine term account reach already good position think able drive strong depth actually get j code place feel good could another think good driver cosentyx growth second half post jcode rolled next question operatoroperatorthank next question come line simon baker redburn atlantic please go aheadsimon baker redburn atlantic analyst thanks much taking question broad question commercial performance highlighted specific reason strength quarter like cosentyx h launch extent broadbased performance seen quarter result change commercial organization underway last couple year wonder extent responsible could give color impacting much left come initiativevas narasimhan chief executive officer yes thanks simon believe probably biggest big picture driver strong performance recent quarter reorganization focus focusing company reminder investor thing elevated yous went geographic model yous international focused portfolio four key therapeutic area focus commercial area nine key drug shifted investment place m investment go growth driver heavy focus yous china japan germany taken together think compounding show broadbased performance see across yous international particularly market like china strong performance think biggest sustainable driver term specific quarter clearly cosentyx performed extremely well putting aside consensus look growth rate kisqali kisqali scemblix strong even pluvicto put aside quarteronquarter growth strong growth rate think also think give u confidence raise guidance full year next question operatoroperatorthank next question come line emmanuel papadakis deutsche bank please go aheademmanuel papadakis deutsche bank analyst thanks taking question since flagged forthcoming asco perhaps question scemblix data detail primary end point going interested see fare obviously physician standard physician choice standard care control versus potential comparators particular signal talk little bit could expect see term standard care competitor primary endpoint indeed secondary willing thought would helpful wellvas narasimhan chief executive officer yes let outline scemblix study designed hopefully give perspective firstline study course third medicine world chronic myelogenous leukemia long history company primary endpoint scemblix versus investigator choice tki goal roughly patient would imatinib primary endpoint scemblix versus overall pool patient intention treat regardless tki first primary endpoint coprimary endpoint scemblix versus gleevec hit primary endpoint clinically meaningful highly statistically significant improvement descriptive secondary endpoint scemblix versus two secondgen tkis disclose full data asco feel good profile medicine safety think one key element semble story already third line setting saw outstanding safety profile think thing look asco presentation overall safety profile scemblix clearly move frontline setting physician want see strong efficacy clean safety profile important note get point filing medicine shortly ultimately launch medicine yous believe portion market drive rapid uptake patient currently secondgen tkis physician practice open switching know element cml market contracted tends use generic imatinib take u longer overall move think one exciting thing scemblix long based targeting rare disease part ira negotiation medicine drive growth decade well next decade yous around globe course one global leader cml think position u well overall thanks question emmanuel next question operatoroperatorthank next question come line richard vosser jp morgan please go aheadrichard vosser jpmorgan chase company analyst hi thanks taking question return cosentyx mentioned launch h sort three time see sizing indication h billion billion indication cosentyx thus see continued potential doubledigit growth next year product suppose one clarification quantification size h contribution stage think pricing stocking first quarter clarify well thanks muchvas narasimhan chief executive officer yeah thanks richard context estimate best public information adalimumab billion sale h historically think market significantly underserved large number patient biologics indication could substantial market think given yet guidance specifically overall size market certainly potential multibilliondollar market think cosentyx opportunity drive significant growth brand try reach billion probably position yet give specific indicationbased guidance cosentyx think combination h iv giant cell arteritis phase ongoing polymyalgia rheumatic indication also well strong performance china give u even conviction get billion peak sale end decade next question operator thanks richardoperatorthank next question come line tim anderson wolfe research please go aheadtim anderson wolfe research analyst thank couple question entresto timing generic entry yous map u tracking term event news flow help inform whether mid good assumption conceived well sometime different point view ex yous timing generic entry guide later similar level uncertainty could wrap china part discussion generic timing wellvas narasimhan chief executive officer yes thanks tim entresto right appeal ongoing circuit court combination patent believe heard ruled second half year important note entresto generic approved yet two citizen petition pending fda basis approval also labeling potential product respect entresto based fact expect generic launch year never exclude course somebody trying something risk separate number patent currently litigated toward end year toward coming period overall make u best estimate yous mid course get better resolution course provide color would also say entresto ira negotiation list would expect jan best understanding least medicare population ira pricing would hold would get better read look september outside united state already include pediatric exclusivity think current guide end reasonable course always looking way adequately depend patent think reasonable assumption point time china moment currently think number different approach key number generic get approved think could reasonably expect potential entry chinese generic sometime course question china enter vbp list course something monitoring better understanding number generic status legally enter vbp list able provide clarity lastly japan currently outlook believe team get back exactly certainly japan current point time hopefully helpful tim thank question next question operatoroperatorthank next question come line richard parkes bnp paribas please go aheadrichard parkes exane bnp paribas analyst hi thanks taking question wondered could help u cost phasing think guidance implying lower margin improvement strong margin improvement saw q know slightly mismodeled last year going q extrapolating margin help u understand phasing term cost year would helpful thank youvas narasimhan chief executive officer thanks richard hand harry harryharry kirsch chief financial officer thank richard overall seen quarter cost growing constant currency roughly driven rd right roughly sga basically flat consequence also full implementation transformation growth restructuring program leaning going one organization locally pharma onco leading country customerfacing function organizational structure leading process see continued benefit course continue leverage new technology leaner process keep driving multiple launch within four therapeutic area significant commercial infrastructure medical infrastructure would expect sga continues quite flattish maybe bit investment certainly significantly sale growth level specialty development spend depends also bit inlicensing agenda clearly placeholder second half year well update q course thing going clear visibility overall good focus cost consciousness va mentioned excellent resource allocation top brand prelaunches always outlook key contribution margin growth expected come sga expect dynamic sale growth year fiveyear basis limited sga growthvas narasimhan chief executive officer thanks harry thanks richard next question operatoroperatorthank next question come line mark purcell morgan stanley please go ahead line openmark purcell morgan stanley analyst thanks much taking question scemblix wonder could help u understand level uptake anticipate firstline setting slide show mbr shown thirdline setting talked sort potential ease identifying specific patient might likely benefit scale versus current standard also wondered scemblix seen early impact part redesign come treatment initiation volume sort comment scemblix across business would great thank youvas narasimhan chief executive officer yeah thanks mark think scemblix would expect would say modest early uptake would work cml one cancer area currently contracted would need work access first couple quarter launch believe given overall data set share asco able drive strong uptake course know well secondgen tkis order billion medicine gleevec billionplus global medicine certainly goal make time leading cml treatment world would face competition least branded competition given demonstrated mmr superiority pooled group gleevec second tkis put u good position time make significant medicine think part redesign really early day u strong sense impact monitoring closely also reading report monitoring really understand impact outofpocket cap shift happening system patient taking medicine think certainly move cap cap would expect general see patient ability fulfill medicine improve cost becomes lower pharmacy counter need see think data really provide color next question operator thanks markoperatorthank next question come line peter welford jefferies please go aheadpeter welford jefferies analyst hi thanks taking question planned proposed morphosis transaction wonder outline much acquisition price considering based getting broad geographical send market approval pelabresib versus hand much transaction described thinking regard ezh also royalty would potentially owe think guess deal potential fitting cost structure business todayvas narasimhan chief executive officer yes thanks peter probably say already said given ongoing share tender offer market previously outlined believe opportunity globally collaborative europe united state exciting opportunity given jakavi business opportunity leverage long history myelofibrosis position myelofibrosis outside united state strong hematology footprint inside united state would see polaperative fitting nicely within global infrastructure yes would also benefit historical royalty particularly ionilumab see opportunity significant medicine immunology cancer think pretty exciting opportunity u get royalty back hopefully drive significant medicine significant medicine royalty freeway lastly company ezh inhibitor prostate cancer think could also interesting u going forward three component saw value deal next question operatoroperatoryour next question come line andrew baum citi please go ahead hello andrew line muteandrew baum citi analyst apology yeah thank going back asc first trial scemblix could expand previous comment dynamic cnl market particularly current market share first line generically versus others medicare versus nonmedicare segmentation help u think barrier entry different segment term authorization step edits thank youvas narasimhan chief executive officer yes andrew couple thing think one see market order imatinib syglivic generic tkis term commercial medicare come back exact data recollection largely evenly split medicare private commercial plan way look overall market opportunity patient secondgen tki opportunity class go generic certainly commercial plan well given compete rebate player would certainly opportunity educate physician great profile particularly around safety profile also efficacy profile hopefully drive switch see early opportunity medicine secondgen tki particularly secondgen tki commercial eventually medicare find patient currently imatinib tend community oncology tend physician long history using imatinib therefore might resistant change take u longer eventually think think move though think good strategy get segment market longer lift u eventually move ex yous yous setting think ex yous really vary geography certainly europe critical u demonstrate differentiation imatinib payer standpoint justify think fair price medicine would expect japan china opportunity strong uptake market think get reimbursed certainly japan welleducated cml physician community think relatively large opportunity well kind highlevel dynamic think asco presentation june provide insight overall market structure seeing opportunity launch medicine thank andrew next question operatoroperatorthank next question come line seamus fernandez guggenheim security please go aheadseamus fernandez guggenheim partner analyst thanks much question really wanted focus igan activity seeing competitive perspective acquisition space wanted get thought acquisition made gain opportunity see space whether atacapan acquisition made know specified lot opportunity interested sort see view validation igan market opportunity thinking competitive landscape going forward thanksvas narasimhan chief executive officer yeah thanks seamus general mean igan believe significant market opportunity patient historically great medicine progress relatively high rate year period toward needing transplantation going dialysis talking segment patient yous alone think sizable opportunity think treatment paradigm course start want historically steroiddriven treatment paradigm think shift wanting somehow manage hemodynamic component medicine patient atrasentan want manage inflammatory component patient along two dimension complement inhibition april inhibition well position atrasentan hemodynamic inhibition iptacopan complement inhibition zakibard also acquired chinook acquisition antiapril component acknowledge competitor particularly antiapril side thing going competitor enter believe company positioned really full range hemodynamic complement antiapril note well course upstream sglt inhibitor also going generic also part early treatment paradigm post sglt inhibitor perhaps generic hypertensive going want move paradigm really potent hemodynamic control also trying get inflammatory component think three medicine allow u wellpositioned patient physician contracting various element yous supply chain also globally approaching think recent acquisition point antiapril whole area exciting right asset others also coming certainly something looking carefully also see expand april inhibition without baf inhibition indication well next question operatoroperatorthank next question come line eric le berrigaud stifel please go aheaderic le berrigaud stifel financial corp analyst thank saw split sale geography leqvio significantly different past ex yous significant yous could maybe elaborate little bit kind agreement reached ex yous territory maybe main three market europe china drug delivered billing drug geographiesvas narasimhan chief executive officer yes thanks eric pleased see leqvio getting steady march upward term overall sale growth outside united state key dynamic first china selfpay mentioned patient day steady growth well term number patient able get treatment china ahead hope get listed full listing nrdl first part next year given strength cardiovascular operation china entresto believe drive pretty significant uptake leqvio time china also reimbursement japan early day launching japan japan significant contributor q expect consistently coming quarter japan significant contribution europe steady uptake commercial market germany well improving performance italy youk mean youk disappointment relative hoped would nonetheless steadily moving well interestingly smaller contributor given number country around globe reimbursement public health agreement place like gulf coast country well market international business also contributing step step come together drive performance saw quarter see hope continue coming quarter steadily get leqvio multibillion dollar outlook given next question operatoroperatorthank next question come line steve scala cowen please go aheadsteve scala td cowen analyst thank much entresto onetime factor driving q sale rebate andor inventory opinion led tracking prescription quarter thank youvas narasimhan chief executive officer yes steve aware onetimers entresto saw strong trx growth saw outstanding growth china think big driver performance saw quarter also steady uptake japan onetimers aware looking harry yet onetimers see underlying performance think driven yous also china japan next question operatoroperatorthank next question come line graham parry bank america please go aheadgraham parry bank america merrill lynch analyst ok thanks followup wondering term charge talking timing earlier assumed guidance adjuvant breast camp kisqali year significant contribution de minimis point flip second one asco event scemblix wondering going position give sort updated peak sale guidance asset obviously lot question call market fishing thank youvas narasimhan chief executive officer yeah thanks graham natalie material contribution really contribution year think something need factored term guidance scemblix take advisement commit one way another certainly take feedback trying guide always tough course even got approval launched medicine really know outlook think got reasonable benchmark cml market gleevec secondgen tkis outlined really believe see present data really bestinclass medicine treat cml launched industry hope live profile next question operatoroperatorthank final question today come line emily field barclaysemily field barclays analyst hi thanks taking question question given morning see phase success itp competitor btk inhibitor wondering given also btk pursuing itp baf inhibition think right mechanism action also prioritizing second line first line believe say lead indication slide thank youvas narasimhan chief executive officer yeah first btk inhibition really tried focus btk inhibitor outside oncology indication mean look indication range pursuing immunology full range h food allergy also idea pursue remibrutinib immunology indication multiple sclerosis tried steer clear oncology setting overall really focus ianilumab oncology also hardtotreat immunology indication based best guidance fda agreement phase study think stepwise approach itp especially subcu medicine like ianilumab yes see move frontline setting think probably best guidance give trying recall looked remibrutinib itp would get back emily recall looked phase program come back studied btk inhibitor indication thanks much think last question really appreciate everybodys time today look forward keeping updated see event asco thank great quarter season wish great springoperatoroperator signoff duration minutescall participantssloan simpson head investor relationsvas narasimhan chief executive officerharry kirsch chief financial officermatt weston ubs analyststeve scala td cowen analystgraham parry bank america merrill lynch analystemily field barclays analystsimon baker redburn atlantic analystemmanuel papadakis deutsche bank analystrichard vosser jpmorgan chase company analysttim anderson wolfe research analystrichard parkes exane bnp paribas analystmark purcell morgan stanley analystpeter welford jefferies analystandrew baum citi analystseamus fernandez guggenheim partner analysteric le berrigaud stifel financial corp analyst nv analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy